Johnson & Johnson (JNJ) › Analysis

Johnson & Johnson (JNJ) stock analysis, November 3, 2026: Uptrend intact, pullback testing the 50-day average

Published November 3, 2026 · updated 2026-11-09 · JNJ chart, levels and live analysis

Update, November 9, 2026

Since the November 3 report, Johnson & Johnson has nudged higher to $277.97, posting a 0.63% gain on the day and extending its 2.74% five‑day advance that outpaced the S&P 500’s –0.92% move while still lagging the health‑care sector XLV’s 0.76% gain. The stock remains just 0.17% below its 52‑week high of 278.43 and continues to trade above the 50‑day SMA at 265.99, keeping the uptrend intact.

The picture holds: the daily price stays above the swing‑zone support at 275.53 and the key breakout target of 281.54 remains unchanged. The stop level of 273.64, derived from the swing‑zone minus a quarter of the 7.57 ATR, also stays in place. A weekly close below the 50‑day SMA at 265.99 would be the trigger that could alter the view.

Recent catalysts include a Phase 1 prostate‑cancer trial showing a 73% PSA response (PR Newswire) and a Phase 3 psoriatic‑arthritis result confirming efficacy of ICOTYDE (PR Newswire). Additionally, J&J’s $100 million investment in psychedelic‑focused Delix Therapeutics (Bloomberg) underscores its growth drive. No new events have shifted the technical outlook.

Johnson & Johnson (JNJ) fell 1.45% to $266.64 on November 3, 2026. That leaves the stock 3.1% below its October 29 closing peak of $275.20 and sitting on its 50-day average. The weekly uptrend is intact, and the balance of evidence for the next two to six weeks leans positive with medium conviction. A breakout above $275 would offer thin reward for the risk, so the case rests on the trend, not on a near-term target.

Why it matters

There was no single JNJ catalyst behind the run to $275.20. The stock rode a rotation out of technology and into drugs. Morningstar named JNJ among the biopharma winners of the tech sell-off. A separate CNBC piece argued that falling rates are now outweighing the AI narrative and pulling money into food, drugs and biotech.

Today's drop is only partly explained. The one company-specific item is the collapse of the planned merger between Smith & Nephew and J&J's orthopaedics division. Reuters noted that the deal had inherent flaws, so its failure is less damaging than it might look. JNJ fell 1.45% on a day when the S&P 500 ETF (SPY) rose 0.23% and the healthcare sector ETF (XLV) slipped 0.17%. That is a larger move than the headline justifies, and it looks more like profit-taking after a strong run than a verdict on the deal.

Much good news was already in the price. JNJ is up 4.36% in a month, 17.61% in six months and 29.11% year to date, against 10.55% for SPY and 19.04% for XLV. The third-quarter earnings beat is already behind it, as Yahoo! Finance noted in a drugmaker earnings roundup. Over five days JNJ lost 0.57% while SPY lost 2.06% and XLV gained 2.85%. The stock held up better than the market but trailed its sector by 3.4 points. Over 50 days the picture is the same: JNJ leads SPY by 2.2% but lags XLV by 6.0%.

The argument about JNJ is mostly about price. On the positive side, CNBC carried Jim Cramer's continued positive view on the stock. On the cautious side, a Yahoo! Finance piece acknowledged the rally, driven partly by Impella heart-pump data, but asked whether the stock is fully valued. It cited a 40.9 P/E at $273.20 and a figure of $240.69. Analysts sit between the two. The 22 covering the stock rate it a buy, with a mean price target of $279.41 and a range of $190 to $320. The price is 4.6% below that mean, so the consensus sees modest upside from here, not a large discount.

What the evidence says

The long-term thesis is intact. JNJ trades above its 40-week average and well above its 200-day average of $247.48. It is 43.35% above its 52-week low of $186.00 and 4.23% below its high of $278.43. This is a mature uptrend that has paused near its highs, not one that has broken.

For the next two to six weeks the balance of evidence leans positive, with medium conviction (2 of 4 points). The daily trend runs with the weekly uptrend, and JNJ is outperforming the broad market over 50 days. The 14-day RSI of 64 shows momentum that is firm but not stretched. The conviction is not higher because only half the checks pass.

The strongest case against that reading is the sector comparison. XLV has gained 10.89% in a month, well ahead of JNJ's 4.36%, so the money rotating into healthcare is reaching other names faster. Today's drop came on volume 58.3% below its 20-day average, and the price has slipped to the 50-day line after a 3.1% pullback. At 40.9 times earnings the stock leaves little room for disappointment. None of this breaks the trend, because price still sits above its key averages and support. It is, though, why conviction stays at medium.

Levels that matter

The structure holds above $265.48, the 50-day average, and the price is only just above it. A close below that line would be the first crack. The trend itself ends below $262.97, a swing zone where buyers previously stepped in. Below that, the next supports are $251.08, then $250.00 and the 200-day average at $247.48.

The breakout level is a daily close above $275.00, a round number, on volume above its 20-day average. From there the first target is the 52-week high of $278.43, and a breakout would be wrong below $263.79, which is the 50-day average minus a quarter of the 14-day ATR. That gives a reward-to-risk of 0.3 to 1. The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target well above $300, the next marker beyond the 52-week high, to get there, and no mapped level before that does.

What would change the picture

A weekly close below $262.97 would change the picture, because it would end the weekly uptrend and turn a pullback into a trend change. The one non-price fact that could do it is a reversal in the rate-driven rotation into drugs. If rates rose again and money moved back toward technology, the main support behind the sector would weaken, and JNJ would be left with a 40.9 P/E and no strong tailwind.

What to watch

Get a message when the JNJ picture changes — the agent team watches the levels and the news for you.Create a free account

More JNJ analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.